(Q24200439)

PubMed publication ID

22513930

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513930%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Recombinant human activated protein C for severe sepsis in neonates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

author name string

Arne Ohlsson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

publication date

18 April 2012

1 reference

PubMed publication ID

22513930

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513930%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

page(s)

CD005385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Drotrecogin alfa (activated) in an infant with gram-negative septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Natural anticoagulant inhibitors: activated Protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Pediatric septic shock and multiple organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

G-CSF and GM-CSF for treating or preventing neonatal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recombinant activated protein C in pediatric sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Advances in sepsis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

New and emerging therapies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

The pathophysiology and treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

21 January 2018

Coagulation in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Mortality rates in pediatric septic shock with and without multiple organ system failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Trends in sepsis-related neonatal mortality in the United States, 1985-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Sepsis: current status, future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

New approaches to the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Intravenous in-line filters for preventing morbidity and mortality in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Intravenous immunoglobulin for suspected or subsequently proven infection in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

21 January 2018

Pediatric considerations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

PRISM III: an updated Pediatric Risk of Mortality score

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Statistical analysis plan of PROWESS SHOCK study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Therapeutic intervention and targets for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 through 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Infections in VLBW infants: studies from the NICHD neonatal research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recombinant human activated protein C, package labeling, and hemorrhage risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Activated protein C for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Risks and benefits of activated protein C treatment for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

The epidemiology of severe sepsis in children in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

The systemic inflammatory response syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Low levels of protein C are associated with poor outcome in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recent developments in the pharmacologic approach to pediatric critical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Recombinant human activated protein C for severe sepsis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

21 January 2018

1 reference

12 December 2020

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

1 reference

12 December 2020

PROTEIN C CONCENTRATE AS ADJUVANT TREATMENT IN NEONATES WITH SEPSIS-INDUCED COAGULOPATHY

1 reference

12 December 2020

[Use of protein C concentrate in critical conditions: clinical experience in pediatric patients with sepsis]

1 reference

12 December 2020

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

1 reference

12 December 2020

Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Use of protein C concentrate in neonatal period.

1 reference

12 December 2020

Pediatric definitions for sepsis: it's about time!

1 reference

12 December 2020

Severe sepsis in a premature neonate: protein C replacement therapy

1 reference

12 December 2020

The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. The International Neonatal Network

1 reference

12 December 2020

A definite role for treatment with activated protein C in sepsis? Standard use is premature

1 reference

12 December 2020

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

1 reference

12 December 2020

Can we RESOLVE the treatment of sepsis?

1 reference

12 December 2020

Recombinant human activated protein C for severe sepsis in a neonate.

1 reference

12 December 2020

Use of activated protein C in a case of paediatric septic shock

1 reference

12 December 2020

Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care

1 reference

12 December 2020

Unblinding plan of PROWESS-SHOCK trial

1 reference

12 December 2020

Substantiating the concerns about recombinant human activated protein C use in sepsis

1 reference

12 December 2020

Drotrecogin alpha (activated) in neonatal septic shock

1 reference

12 December 2020

Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants

1 reference

12 December 2020

Treatment of acute infectious purpura fulminans with activated protein C

1 reference

12 December 2020

Treatment with recombinant human activated protein C: one size does not fit all.

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure

1 reference

12 December 2020

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005385.PUB3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD005385.PUB3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984667&resulttype=core&format=json

14 May 2020

PubMed publication ID

22513930

1 reference